Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Cancer Sci. 2021 Mar;112(3):1150-1160. doi: 10.1111/cas.14808. Epub 2021 Feb 3.
This study focused on children as well as adolescents and young adults (AYAs) and aimed to examine trends in survival of leukemia over time using population-based cancer registry data from Osaka, Japan. The study subjects comprised 2254 children (0-14 years) and 2,905 AYAs (15-39 years) who were diagnosed with leukemia during 1975-2011. Leukemia was divided into four types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and other leukemias. We analyzed 5-year overall survival probability (5y-OS), using the Kaplan-Meier method and expressed time trends using the joinpoint regression model. For recently diagnosed (2006-2011) patients, a Cox proportional hazards model was applied to determine predictors of 5y-OS, using age group, gender, and treatment hospital as covariates. Over the 37-year period, 5y-OS greatly improved among both children and AYAs, for each leukemia type. Among AYAs, 5y-OS of ALL improved, especially after 2000 (65% in 2006-2011), when the pediatric regimen was introduced but was still lower than that among children (87% in 2006-2011, P < .001). Survival improvement was most remarkable in CML, and its 5y-OS was over 90% among both children and AYAs after the introduction of molecularly targeted therapy with tyrosine kinase inhibitors. Among patients with recently diagnosed AML, the risk of death was significantly higher for patients treated at nondesignated hospitals than those treated at designated cancer care hospitals. The changes in survival improvement coincided with the introduction of treatment regimens or molecularly targeted therapies. Patient centralization might be one option which would improve survival.
本研究聚焦于儿童、青少年和青年成人(AYA),旨在利用日本大阪的基于人群的癌症登记数据,研究白血病随时间推移的生存趋势。研究对象包括 2254 名儿童(0-14 岁)和 2905 名 AYA(15-39 岁),他们在 1975-2011 年间被诊断患有白血病。白血病分为四种类型:急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML)、慢性髓细胞白血病(CML)和其他白血病。我们使用 Kaplan-Meier 方法分析了 5 年总生存率(5y-OS),并用 joinpoint 回归模型表示时间趋势。对于最近诊断的(2006-2011 年)患者,使用 Cox 比例风险模型,以年龄组、性别和治疗医院为协变量,确定 5y-OS 的预测因素。在 37 年期间,每种白血病类型的儿童和 AYA 的 5y-OS 均显著提高。在 AYA 中,ALL 的 5y-OS 得到改善,尤其是在 2000 年后(2006-2011 年为 65%),当时引入了儿科方案,但仍低于儿童(2006-2011 年为 87%,P<.001)。CML 的生存改善最为显著,在引入分子靶向治疗酪氨酸激酶抑制剂后,儿童和 AYA 的 5y-OS 均超过 90%。在最近诊断为 AML 的患者中,与在指定癌症治疗医院治疗的患者相比,在非指定医院治疗的患者死亡风险显著更高。生存改善的变化与治疗方案或分子靶向治疗的引入相吻合。患者集中化可能是提高生存率的一种选择。